Assessing Neurofilaments as Biomarkers of Neuroprotection in Progressive Multiple Sclerosis: From the MS-STAT Randomized Controlled Trial

• Published in: Neurology : neuroimmunology & neuroinflammation 2022-03, Vol.9 (2)
• Main Authors: Williams, Thomas E., Holdsworth, Katherine P., Nicholas, Jennifer M., Eshaghi, Arman, Katsanouli, Theodora, Wellington, Henrietta, Heslegrave, Amanda, Zetterberg, Henrik, Frost, Chris, Chataway, Jeremy
• Format: Article
• Language: English
• Subjects: Adult; Biomarkers; blood; Chronic Progressive; diagnosis; drug effects; drug therapy; Female; Health Care; Humans; Male; Middle Aged; Multiple Sclerosis; Multiple Sclerosis, Chronic Progressive - blood; Multiple Sclerosis, Chronic Progressive - diagnosis; Multiple Sclerosis, Chronic Progressive - drug therapy; Neurofilament Proteins; Neurofilament Proteins - blood; Neurofilament Proteins - drug effects; Neuroprotective Agents; Neuroprotective Agents - pharmacology; Neurosciences; Neurovetenskaper; Outcome Assessment; Outcome Assessment, Health Care; pharmacology; Simvastatin; Simvastatin - pharmacology
• ISSN: 2332-7812; 2332-7812
• DOI: 10.1212/NXI.0000000000001130

Improved biomarkers of neuroprotective treatment are needed in progressive multiple sclerosis (PMS) to facilitate more efficient phase 2 trial design. The MS-STAT randomized controlled trial supported the neuroprotective potential of high-dose simvastatin in secondary progressive MS (SPMS). Here, we analyze serum from the MS-STAT trial to assess the extent to which neurofilament light (NfL) and neurofilament heavy (NfH), both promising biomarkers of neuroaxonal injury, may act as biomarkers of simvastatin treatment in SPMS. The MS-STAT trial randomized patients to 80 mg simvastatin or placebo. Serum was analyzed for NfL and NfH using Simoa technology. We used linear mixed models to investigate the treatment effects of simvastatin compared with placebo on NfL and NfH. Additional models examined the relationships between neurofilaments and MRI and clinical measures of disease severity. A total of 140 patients with SPMS were included. There was no evidence for a simvastatin treatment effect on NfL or NfH: compared with placebo, NfL was 1.2% lower (95% CI 10.6% lower to 9.2% higher; = 0.820) and NfH was 0.4% lower (95% CI 18.4% lower to 21.6% higher; = 0.969) in the simvastatin treatment group. Secondary analyses suggested that higher NfL was associated with greater subsequent whole brain atrophy, higher T2 lesion volume, and more new/enlarging T2 lesions in the previous 12 months, as well as greater physical disability. There were no significant associations between NfH and MRI or clinical variables. We found no evidence of a simvastatin treatment effect on serum neurofilaments. While confirmation of the neuroprotective benefits of simvastatin is awaited from the ongoing phase 3 study (NCT03387670), our results suggest that treatments capable of slowing the rate of whole brain atrophy in SPMS, such as simvastatin, may act via mechanisms largely independent of neuroaxonal injury, as quantified by NfL. This has important implications for the design of future phase 2 clinical trials in PMS. MS-STAT: NCT00647348. This study provides class I evidence that simvastatin treatment does not have a large impact on either serum NfL or NfH, as quantified in this study, in SPMS.